Antibody response after vaccination with 23-valent pneumococcal polysaccharide vaccine

Antibody response after vaccination with 23-valent pneumococcal polysaccharide vaccine - Antibody response after vaccination with 23-valent pneumococcal polysaccharide vaccine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014254

Enrollment

Registered

2014-06-16

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic lung disease

Interventions

Single vaccination of pneumococcal polysaccharide vaccine (0.5 ml) intramuscularly or subcutaneously

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with chronic lung disease 2) Patients who understand the procedure of this study and give informed consent in written voluntarily before participation in the study.

Exclusion criteria

Exclusion criteria: 1) Patients who have already received pneumococcal vaccine 2) Patients who have fever 3) Allergy against vaccine contents 4) Pregnancy 5) When the doctor decides the patient's condition is inappropriate

Design outcomes

Primary

Measure	Time frame
Anti pneumococcal capsular polysaccharide IgG antibody	—

Countries

Japan

Contacts

Public ContactHideki Kusagaya

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

kusagaya0726@gmail.com053-435-2263

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026